詳細検索

詳細検索

お問い合わせ

Global Biologics CDMO Market Outlook, InDepth Analysis & Forecast to 2032

Global Biologics CDMO Market Outlook, InDepth Analysis & Forecast to 2032


バイオ医薬品CDMOの世界市場 2026-2032年

The global Biologics CDMO market is projected to grow from US$ 98436 million in 2025 to US$ 178798 million by 2032, at a CAGR of 8.9% (2026-2032), driven by critical product segments and diverse en... もっと見る

 

 

出版社
QYResearch
QYリサーチ
出版年月
2026年11月15日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報/注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Biologics CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Biologics CDMO Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Biologics CDMO Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Biologics CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Biologics CDMO Revenue by Region (US$ Million), 2021-2026
Table 7. Global Biologics CDMO Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Biologics CDMO Revenue by Players (US$ Million), 2021-2026
Table 10. Global Biologics CDMO Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics CDMO Revenue, 2025
Table 13. Global Biologics CDMO Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Biologics CDMO Companies Headquarters
Table 15. Global Biologics CDMO Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Biologics CDMO Revenue by Type (US$ Million), 2021-2026
Table 19. Global Biologics CDMO Revenue by Type (US$ Million), 2027-2032
Table 20. Global Biologics CDMO Revenue by Manufacturing Service Type (US$ Million), 2021-2026
Table 21. Global Biologics CDMO Revenue by Manufacturing Service Type (US$ Million), 2027-2032
Table 22. Global Biologics CDMO Revenue by Development and Commercialization Stage (US$ Million), 2021-2026
Table 23. Global Biologics CDMO Revenue by Development and Commercialization Stage (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Biologics CDMO Revenue by Application (US$ Million), 2021-2026
Table 26. Global Biologics CDMO Revenue by Application (US$ Million), 2027-2032
Table 27. Biologics CDMO High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Biologics CDMO Growth Accelerators and Market Barriers
Table 31. North America Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Biologics CDMO Growth Accelerators and Market Barriers
Table 33. Europe Biologics CDMO Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Biologics CDMO Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Biologics CDMO Investment Opportunities and Key Challenges
Table 37. Central and South America Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Biologics CDMO Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Group AG Corporation Information
Table 41. Lonza Group AG Description and Major Businesses
Table 42. Lonza Group AG Product Features and Attributes
Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Group AG Revenue Proportion by Product in 2025
Table 45. Lonza Group AG Revenue Proportion by Application in 2025
Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Group AG Biologics CDMO SWOT Analysis
Table 48. Lonza Group AG Recent Developments
Table 49. Samsung Biologics Co., Ltd. Corporation Information
Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses
Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes
Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025
Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025
Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025
Table 56. Samsung Biologics Co., Ltd. Biologics CDMO SWOT Analysis
Table 57. Samsung Biologics Co., Ltd. Recent Developments
Table 58. WuXi Biologics (Cayman) Inc. Corporation Information
Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses
Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes
Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025
Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025
Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025
Table 65. WuXi Biologics (Cayman) Inc. Biologics CDMO SWOT Analysis
Table 66. WuXi Biologics (Cayman) Inc. Recent Developments
Table 67. FUJIFILM Holdings Corporation Corporation Information
Table 68. FUJIFILM Holdings Corporation Description and Major Businesses
Table 69. FUJIFILM Holdings Corporation Product Features and Attributes
Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025
Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025
Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025
Table 74. FUJIFILM Holdings Corporation Biologics CDMO SWOT Analysis
Table 75. FUJIFILM Holdings Corporation Recent Developments
Table 76. AGC Inc. Corporation Information
Table 77. AGC Inc. Description and Major Businesses
Table 78. AGC Inc. Product Features and Attributes
Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. AGC Inc. Revenue Proportion by Product in 2025
Table 81. AGC Inc. Revenue Proportion by Application in 2025
Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025
Table 83. AGC Inc. Biologics CDMO SWOT Analysis
Table 84. AGC Inc. Recent Developments
Table 85. Boehringer Ingelheim International GmbH Corporation Information
Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses
Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes
Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Boehringer Ingelheim International GmbH Recent Developments
Table 90. Thermo Fisher Scientific Inc. Corporation Information
Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Thermo Fisher Scientific Inc. Recent Developments
Table 95. Novo Holdings A/S Corporation Information
Table 96. Novo Holdings A/S Description and Major Businesses
Table 97. Novo Holdings A/S Product Features and Attributes
Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Novo Holdings A/S Recent Developments
Table 100. Rentschler Biopharma SE Corporation Information
Table 101. Rentschler Biopharma SE Description and Major Businesses
Table 102. Rentschler Biopharma SE Product Features and Attributes
Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Rentschler Biopharma SE Recent Developments
Table 105. KBI Biopharma, Inc. Corporation Information
Table 106. KBI Biopharma, Inc. Description and Major Businesses
Table 107. KBI Biopharma, Inc. Product Features and Attributes
Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. KBI Biopharma, Inc. Recent Developments
Table 110. Ajinomoto Co., Inc. Corporation Information
Table 111. Ajinomoto Co., Inc. Description and Major Businesses
Table 112. Ajinomoto Co., Inc. Product Features and Attributes
Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Ajinomoto Co., Inc. Recent Developments
Table 115. LOTTE BIOLOGICS Corporation Information
Table 116. LOTTE BIOLOGICS Description and Major Businesses
Table 117. LOTTE BIOLOGICS Product Features and Attributes
Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. LOTTE BIOLOGICS Recent Developments
Table 120. Polpharma Biologics Corporation Information
Table 121. Polpharma Biologics Description and Major Businesses
Table 122. Polpharma Biologics Product Features and Attributes
Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Polpharma Biologics Recent Developments
Table 125. EirGenix, Inc. Corporation Information
Table 126. EirGenix, Inc. Description and Major Businesses
Table 127. EirGenix, Inc. Product Features and Attributes
Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. EirGenix, Inc. Recent Developments
Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information
Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses
Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes
Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments
Table 135. Simtra BioPharma Solutions Corporation Information
Table 136. Simtra BioPharma Solutions Description and Major Businesses
Table 137. Simtra BioPharma Solutions Product Features and Attributes
Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Simtra BioPharma Solutions Recent Developments
Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses
Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes
Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
Table 145. Piramal Pharma Limited Corporation Information
Table 146. Piramal Pharma Limited Description and Major Businesses
Table 147. Piramal Pharma Limited Product Features and Attributes
Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Piramal Pharma Limited Recent Developments
Table 150. AbbVie Inc. Corporation Information
Table 151. AbbVie Inc. Description and Major Businesses
Table 152. AbbVie Inc. Product Features and Attributes
Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. AbbVie Inc. Recent Developments
Table 155. Emergent BioSolutions Inc. Corporation Information
Table 156. Emergent BioSolutions Inc. Description and Major Businesses
Table 157. Emergent BioSolutions Inc. Product Features and Attributes
Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Emergent BioSolutions Inc. Recent Developments
Table 160. SK pharmteco Corporation Information
Table 161. SK pharmteco Description and Major Businesses
Table 162. SK pharmteco Product Features and Attributes
Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. SK pharmteco Recent Developments
Table 165. Oxford Biomedica plc Corporation Information
Table 166. Oxford Biomedica plc Description and Major Businesses
Table 167. Oxford Biomedica plc Product Features and Attributes
Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Oxford Biomedica plc Recent Developments
Table 170. WuXi XDC Cayman Inc. Corporation Information
Table 171. WuXi XDC Cayman Inc. Description and Major Businesses
Table 172. WuXi XDC Cayman Inc. Product Features and Attributes
Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. WuXi XDC Cayman Inc. Recent Developments
Table 175. Porton Pharma Solutions Ltd. Corporation Information
Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses
Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes
Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Porton Pharma Solutions Ltd. Recent Developments
Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses
Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes
Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
Table 185. BioVectra Inc. Corporation Information
Table 186. BioVectra Inc. Description and Major Businesses
Table 187. BioVectra Inc. Product Features and Attributes
Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. BioVectra Inc. Recent Developments
Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information
Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses
Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes
Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments
Table 195. Recipharm AB Corporation Information
Table 196. Recipharm AB Description and Major Businesses
Table 197. Recipharm AB Product Features and Attributes
Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Recipharm AB Recent Developments
Table 200. Minaris Regenerative Medicine Corporation Information
Table 201. Minaris Regenerative Medicine Description and Major Businesses
Table 202. Minaris Regenerative Medicine Product Features and Attributes
Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Minaris Regenerative Medicine Recent Developments
Table 205. Cellipont Bioservices Corporation Information
Table 206. Cellipont Bioservices Description and Major Businesses
Table 207. Cellipont Bioservices Product Features and Attributes
Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Cellipont Bioservices Recent Developments
Table 210. Andelyn Biosciences Corporation Information
Table 211. Andelyn Biosciences Description and Major Businesses
Table 212. Andelyn Biosciences Product Features and Attributes
Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Andelyn Biosciences Recent Developments
Table 215. Danaher Corporation Corporation Information
Table 216. Danaher Corporation Description and Major Businesses
Table 217. Danaher Corporation Product Features and Attributes
Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Danaher Corporation Recent Developments
Table 220. BioCina Corporation Information
Table 221. BioCina Description and Major Businesses
Table 222. BioCina Product Features and Attributes
Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. BioCina Recent Developments
Table 225. Syngene International Limited Corporation Information
Table 226. Syngene International Limited Description and Major Businesses
Table 227. Syngene International Limited Product Features and Attributes
Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Syngene International Limited Recent Developments
Table 230. Aragen Life Sciences Corporation Information
Table 231. Aragen Life Sciences Description and Major Businesses
Table 232. Aragen Life Sciences Product Features and Attributes
Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. Aragen Life Sciences Recent Developments
Table 235. MabPlex International Corporation Information
Table 236. MabPlex International Description and Major Businesses
Table 237. MabPlex International Product Features and Attributes
Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. MabPlex International Recent Developments
Table 240. GenScript Biotech Corporation Corporation Information
Table 241. GenScript Biotech Corporation Description and Major Businesses
Table 242. GenScript Biotech Corporation Product Features and Attributes
Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. GenScript Biotech Corporation Recent Developments
Table 245. Chime Biologics Corporation Information
Table 246. Chime Biologics Description and Major Businesses
Table 247. Chime Biologics Product Features and Attributes
Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Chime Biologics Recent Developments
Table 250. Hangzhou HJB Corporation Information
Table 251. Hangzhou HJB Description and Major Businesses
Table 252. Hangzhou HJB Product Features and Attributes
Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Hangzhou HJB Recent Developments
Table 255. BiBo Pharma Corporation Information
Table 256. BiBo Pharma Description and Major Businesses
Table 257. BiBo Pharma Product Features and Attributes
Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 259. BiBo Pharma Recent Developments
Table 260. Technologies, Platforms and Infrastructure
Table 261. Distributors List
Table 262. Market Trends and Market Evolution
Table 263. Market Drivers and Opportunities
Table 264. Market Challenges, Risks, and Restraints
Table 265. Research Programs/Design for This Report
Table 266. Key Data Information from Secondary Sources
Table 267. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Biologics CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Biological Agent Product Picture
Figure 3. Biosimilar Drug Product Picture
Figure 4. Global Biologics CDMO Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 5. Drug Substance Manufacturing Product Picture
Figure 6. Drug Product Manufacturing Product Picture
Figure 7. Integrated Drug Substance and Drug Product Manufacturing Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biologics CDMO Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Preclinical and IND-enabling Manufacturing Product Picture
Figure 11. Phase I Clinical Manufacturing Product Picture
Figure 12. Phase II Clinical Manufacturing Product Picture
Figure 13. Phase III Clinical Manufacturing Product Picture
Figure 14. Others Product Picture
Figure 15. Global Biologics CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Oncology
Figure 17. Immunology and Autoimmune Diseases
Figure 18. Infectious Diseases and Vaccines
Figure 19. Metabolic and Endocrine Diseases
Figure 20. Neurological Diseases
Figure 21. Others
Figure 22. Biologics CDMO Report Years Considered
Figure 23. Global Biologics CDMO Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 24. Global Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 25. Global Biologics CDMO Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 26. Global Biologics CDMO Revenue-Based Market Share by Region (2021-2032)
Figure 27. Global Biologics CDMO Revenue-Based Market Share Ranking (2025)
Figure 28. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 29. Biological Agent Revenue-Based Market Share by Player in 2025
Figure 30. Biosimilar Drug Revenue-Based Market Share by Player in 2025
Figure 31. Global Biologics CDMO Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Biologics CDMO Revenue-Based Market Share by Manufacturing Service Type (2021-2032)
Figure 33. Global Biologics CDMO Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
Figure 34. Global Biologics CDMO Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 37. North America Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 39. Canada Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 40. Mexico Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 41. Europe Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 43. Europe Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 45. France Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 46. U.K. Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 47. Italy Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 48. Russia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 53. Japan Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 54. South Korea Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 55. Australia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 56. India Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 60. Philippines Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 61. Singapore Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 64. Central and South America Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 66. Argentina Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 71. Israel Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 72. Egypt Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 73. South Africa Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 74. Biologics CDMO Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed

 

ページTOPに戻る


 

Summary

The global Biologics CDMO market is projected to grow from US$ 98436 million in 2025 to US$ 178798 million by 2032, at a CAGR of 8.9% (2026-2032), driven by critical product segments and diverse end‑use applications.

Biologics CDMO (Contract Development and Manufacturing Organization) refers to specialized outsourced services that support the development, process optimization, clinical manufacturing, and commercial production of biological pharmaceutical products. These services are provided to biotechnology companies, pharmaceutical manufacturers, and emerging drug developers seeking advanced bioprocessing capabilities and scalable manufacturing infrastructure. The market covers contract development and manufacturing activities for monoclonal antibodies, recombinant proteins, vaccines, antibody-drug conjugates (ADCs), bispecific antibodies, and selected advanced biological therapies. Core services include cell line development, cell banking, upstream and downstream process development, analytical method development, process characterization, formulation development, technology transfer, clinical and commercial drug substance manufacturing, sterile fill-finish, process validation, and quality control. Biologics CDMO operations commonly utilize mammalian cell culture, microbial fermentation, single-use bioreactors, stainless-steel production systems, chromatography purification, filtration technologies, and advanced analytical platforms. Manufacturing and development activities are conducted under applicable Good Manufacturing Practice (GMP) standards and regulatory requirements. The market focuses on integrated development and manufacturing services throughout the biological product lifecycle, enabling pharmaceutical developers to access specialized technologies, reduce internal infrastructure requirements, accelerate clinical development, and establish reliable commercial supply capabilities.

Key Findings
Biologics CDMO integrates biological process development, clinical manufacturing, and commercial production services
Monoclonal antibodies remain a major product category supported by established mammalian cell culture platforms
North America, Europe, and Asia-Pacific form the principal regional markets for biologics development and manufacturing outsourcing
ADCs and bispecific antibodies are important emerging segments requiring specialized development and manufacturing technologies

Market Trends
The Biologics CDMO industry is evolving from conventional manufacturing outsourcing toward integrated development and manufacturing partnerships covering the entire biological drug lifecycle. Pharmaceutical and biotechnology companies increasingly prefer service providers capable of supporting cell line development, process optimization, analytical development, clinical production, regulatory validation, and commercial manufacturing within coordinated technology platforms. This approach reduces the operational complexity associated with transferring products between multiple service providers and improves continuity between development and manufacturing stages. Standardized mammalian cell culture platforms, high-performance expression systems, single-use manufacturing technologies, and modular production facilities are improving process flexibility and accelerating project execution. Meanwhile, the growing complexity of ADCs, bispecific antibodies, and other advanced biological modalities is encouraging investment in specialized development capabilities, high-resolution analytical methods, advanced purification technologies, and integrated drug substance and drug product services. Digital process monitoring, automated quality management, artificial intelligence-assisted process optimization, and data-driven manufacturing control are becoming increasingly important for improving production consistency and operational efficiency. As a result, the industry is shifting toward technology-enabled, flexible, and globally coordinated manufacturing networks, with service differentiation increasingly determined by development speed, technical complexity, process robustness, and lifecycle management capabilities.

Market Dynamics
Drivers
The continued expansion of biological drug pipelines is a primary driver of the Biologics CDMO market. Increasing development activity in monoclonal antibodies, recombinant proteins, biosimilars, ADCs, and bispecific antibodies is generating demand for specialized process development and manufacturing services. Emerging biotechnology companies often operate with limited internal production infrastructure and rely on external CDMO partners to support clinical development while controlling capital expenditure. Established pharmaceutical manufacturers also increasingly use outsourcing partnerships to improve capacity flexibility, access specialized technologies, and accelerate product development timelines. The transition of biological drug candidates from early clinical development into late-stage trials and commercial production creates opportunities for service providers to establish longer-term customer relationships. In addition, increasingly stringent regulatory requirements and the technical complexity of biological manufacturing strengthen demand for experienced service providers with validated production platforms, comprehensive quality management systems, and international regulatory capabilities.

Restraints
The Biologics CDMO industry faces significant capital requirements, long facility construction and qualification cycles, and substantial operating costs. Advanced bioprocessing facilities require specialized equipment, controlled production environments, analytical laboratories, validated utility systems, and experienced scientific and engineering personnel. High fixed costs increase sensitivity to capacity utilization, particularly when clinical manufacturing projects are delayed or commercial production volumes fall below expectations. Development and manufacturing activities also depend on specialized raw materials, culture media, chromatography resins, filtration membranes, and single-use components, which can create procurement and cost pressures. Biological product development involves complex technology transfer, process characterization, and validation procedures, limiting the speed at which projects can move between manufacturing facilities. Additional constraints arise from regulatory approval timelines, intellectual property considerations, and differences in manufacturing requirements across biological modalities. These factors can increase project costs and limit operating flexibility, particularly for smaller service providers.

Opportunities
Advanced biological therapeutics represent an important growth opportunity for Biologics CDMO providers. ADCs, bispecific and multispecific antibodies, cell and gene therapies, and other complex biological products frequently require specialized development platforms and manufacturing technologies that are expensive for biotechnology developers to establish internally. Service providers offering integrated cell line development, process development, bioconjugation, analytical characterization, drug substance manufacturing, and sterile fill-finish can expand their participation in customer development programs. Biosimilars also create opportunities for CDMO platforms capable of combining high product quality with competitive manufacturing economics. Expansion into late-stage clinical and commercial manufacturing offers additional potential for recurring revenue and longer contractual relationships. Geographical diversification is another strategic opportunity as pharmaceutical companies increasingly evaluate regional production networks to improve supply continuity and address regulatory and geopolitical considerations. Continued adoption of process intensification, continuous bioprocessing, advanced automation, and digital manufacturing tools may further improve productivity and reduce manufacturing costs.

Challenges
Biologics CDMO providers must manage substantial technical, regulatory, commercial, and operational risks throughout the biological product lifecycle. Clinical development projects are subject to uncertain outcomes, and unsuccessful trials or changes in pharmaceutical development priorities can lead to project cancellations and reduced manufacturing demand. Commercial manufacturing requires consistent quality, process reproducibility, reliable supply, and compliance with increasingly complex international regulatory requirements. Rapid investment in large-scale production facilities can create periods of underutilized capacity and intensify pricing competition when customer demand develops more slowly than anticipated. At the same time, different biological modalities require distinct development and manufacturing technologies, making platform standardization and flexible capacity allocation challenging. International operations are further affected by trade restrictions, cross-border technology transfer requirements, intellectual property considerations, and pharmaceutical supply chain policies. Competition for qualified scientific, engineering, quality assurance, and regulatory personnel also creates operational pressure. Maintaining technological competitiveness while achieving stable utilization and sustainable profitability remains a central challenge for industry participants.

Value Chain Analysis

The Biologics CDMO value chain extends from upstream technology and raw material suppliers through integrated development and manufacturing service providers to pharmaceutical companies and biological therapy developers. Upstream participants supply cell culture media, expression systems, biological reagents, bioreactors, single-use assemblies, filtration membranes, chromatography resins, analytical instruments, and sterile packaging materials. These inputs directly influence cell growth performance, purification efficiency, process reliability, and manufacturing costs. At the center of the value chain, CDMO providers integrate cell line development, cell banking, process development, analytical characterization, formulation, technology transfer, GMP manufacturing, process validation, and sterile fill-finish. Technical integration between these activities is an important source of value creation because it improves process continuity, reduces repeated development work, and supports more efficient progression from laboratory-scale development to commercial production.

Downstream customers consist primarily of biotechnology companies, multinational pharmaceutical manufacturers, biosimilar developers, and specialized biological therapy companies. Their purchasing decisions depend on technical capability, regulatory experience, manufacturing capacity, development timelines, intellectual property protection, and long-term supply reliability. Revenue models typically combine project-based development fees, clinical manufacturing contracts, milestone-related services, and recurring commercial manufacturing agreements. Early-stage development services are generally more dependent on scientific expertise and project execution, while commercial manufacturing requires substantial capital investment and benefits from stable production volumes and high capacity utilization. Specialized services such as complex antibody development, ADC conjugation, and advanced analytical characterization may support differentiated pricing because of their technical requirements. Profitability ultimately depends on project conversion rates, manufacturing yields, fixed-cost absorption, regulatory performance, and the ability to retain customers as products advance through development stages.

Segment Insights
The Biologics CDMO market can be analyzed through biological product type, development and manufacturing service, production technology, and clinical development stage. Monoclonal antibodies represent a major established product segment because of their broad therapeutic applications, mature expression technologies, and extensive clinical and commercial manufacturing requirements. Recombinant proteins and biosimilars represent additional established markets, with customer demand emphasizing process robustness, product consistency, and cost-effective large-scale production. Mammalian cell culture remains a key production technology for complex therapeutic proteins, particularly products requiring specific post-translational modifications. Microbial expression systems remain important for selected recombinant proteins and biological products. The appropriate manufacturing platform depends on molecular structure, biological activity, production scale, quality requirements, and process economics.

From a service perspective, development services and manufacturing services have different commercial characteristics but are increasingly connected within integrated CDMO business models. Cell line development, analytical development, and process optimization establish the technical foundation for later production activities, while clinical manufacturing supports investigational product supply and regulatory progression. Commercial manufacturing provides opportunities for longer-term contracts and recurring production revenue, although conversion from clinical projects remains dependent on successful development and regulatory approval. Drug substance manufacturing represents a technically intensive part of the market, while sterile fill-finish and formulation services are gaining strategic importance as customers seek integrated production solutions. ADCs and bispecific antibodies represent important specialized segments, requiring additional capabilities in molecular characterization, conjugation, purification, and product stability management. Providers capable of integrating these specialized technologies into scalable manufacturing platforms are positioned to capture higher-value development and manufacturing projects.

Downstream Market Opportunities
Downstream demand for Biologics CDMO services is primarily associated with oncology, immunology, inflammatory diseases, infectious diseases, rare diseases, and other therapeutic areas involving biological medicines. Oncology represents an important opportunity because the development of monoclonal antibodies, bispecific antibodies, and ADCs creates complex process development, analytical testing, and commercial manufacturing requirements. Immunology and chronic inflammatory disease therapies support demand for established biological manufacturing platforms and reliable long-term commercial supply. Biosimilar developers increasingly require CDMO partners that can maintain consistent product quality while reducing production costs and supporting market entry. Emerging biotechnology enterprises represent another important customer group, particularly when advancing drug candidates from preclinical research into clinical development and commercial preparation. These companies frequently rely on external service providers for cell line development, process characterization, GMP production, and regulatory manufacturing support. As biological drug pipelines become more diverse, CDMO providers with integrated development, clinical manufacturing, and commercial supply capabilities have opportunities to increase customer engagement across multiple product stages and therapeutic applications.

Regional Insights
North America represents one of the principal regional markets for Biologics CDMO services, supported by its extensive biotechnology ecosystem, established pharmaceutical industry, and substantial biological drug development activity. The United States is particularly important for innovative therapeutic development, early-stage biotechnology outsourcing, and advanced biological manufacturing technologies. Regional pharmaceutical customers place significant emphasis on regulatory compliance, manufacturing quality, intellectual property protection, and supply chain resilience. Continued investment in domestic manufacturing infrastructure is strengthening the region's capacity to support commercial-scale biological drug production. Europe also maintains a strong position in the Biologics CDMO industry, supported by established pharmaceutical production capabilities, advanced bioprocessing technologies, and mature regulatory systems. Switzerland, Germany, Ireland, and other European manufacturing locations serve international customers through specialized biological production facilities and integrated development and manufacturing networks.

Asia-Pacific is an important region for manufacturing capacity expansion, technology investment, and the development of integrated biologics services. South Korea has established substantial large-scale mammalian cell culture capacity and a strong presence in commercial biological manufacturing. China has developed broad service capabilities spanning biological research support, cell line development, process optimization, clinical manufacturing, and commercial production. Japan and Singapore contribute specialized manufacturing technologies, experienced pharmaceutical production infrastructure, and high-quality regulatory manufacturing capabilities. Regional competitiveness increasingly reflects differences in manufacturing scale, technical specialization, operating efficiency, international regulatory experience, and access to global pharmaceutical customers. Latin America and the Middle East represent smaller but developing opportunities, particularly in vaccine production, regional pharmaceutical supply, technology transfer, and localized biological manufacturing. Across regions, pharmaceutical companies are increasingly evaluating manufacturing partnerships based on regulatory compatibility, geographical diversification, and long-term operational reliability.

Competitive Landscape Analysis
The Biologics CDMO market is characterized by competition between large integrated multinational service providers and specialized companies focusing on particular biological modalities, development technologies, or manufacturing processes. Established industry participants include Lonza, Samsung Biologics, WuXi Biologics, and FUJIFILM Biotechnologies, each with differentiated operating capabilities and strategic priorities. Lonza operates an extensive biological development and manufacturing platform covering mammalian and microbial production, bioconjugation, and drug product manufacturing. Its global manufacturing infrastructure and technical expertise support customers across multiple stages of biological drug development and commercialization. Samsung Biologics emphasizes large-scale mammalian cell culture manufacturing, standardized production platforms, and integrated contract development and manufacturing services, positioning its operations around manufacturing efficiency, quality control, and long-term commercial partnerships. WuXi Biologics provides integrated biological development and manufacturing services, with particular exposure to monoclonal antibodies, bispecific antibodies, and ADC-related programs. In 2025, the company reported 945 integrated projects, including 74 Phase III projects and 25 commercial manufacturing projects, while adding 209 new integrated projects during the year. Approximately two-thirds of these new projects involved bispecific antibodies and ADCs, illustrating the increasing importance of complex biological modalities. FUJIFILM Biotechnologies is expanding commercial-scale manufacturing capabilities through its international production network. Its Holly Springs facility in North Carolina opened in September 2025 with an initial configuration of eight 20,000-liter mammalian cell culture bioreactors, strengthening its large-scale manufacturing capabilities. Overall, industry competition increasingly centers on integrated service coverage, technical specialization, regulatory execution, capacity utilization, manufacturing quality, and customer lifecycle management. Large providers benefit from established infrastructure and international production networks, while specialized CDMOs compete through flexibility, innovative technology platforms, and expertise in complex biological products.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Biologics CDMO market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Lonza Group AG
Samsung Biologics Co., Ltd.
WuXi Biologics (Cayman) Inc.
FUJIFILM Holdings Corporation
AGC Inc.
Boehringer Ingelheim International GmbH
Thermo Fisher Scientific Inc.
Novo Holdings A/S
Rentschler Biopharma SE
KBI Biopharma, Inc.
Ajinomoto Co., Inc.
LOTTE BIOLOGICS
Polpharma Biologics
EirGenix, Inc.
Richter-Helm BioLogics GmbH & Co. KG
Simtra BioPharma Solutions
Vetter Pharma-Fertigung GmbH & Co. KG
Piramal Pharma Limited
AbbVie Inc.
Emergent BioSolutions Inc.
SK pharmteco
Oxford Biomedica plc
WuXi XDC Cayman Inc.
Porton Pharma Solutions Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd.
BioVectra Inc.
Bora Pharmaceuticals Co., Ltd.
Recipharm AB
Minaris Regenerative Medicine
Cellipont Bioservices
Andelyn Biosciences
Danaher Corporation
BioCina
Syngene International Limited
Aragen Life Sciences
MabPlex International
GenScript Biotech Corporation
Chime Biologics
Hangzhou HJB
BiBo Pharma

Segment by Type
Biological Agent
Biosimilar Drug

Segment by Manufacturing Service Type
Drug Substance Manufacturing
Drug Product Manufacturing
Integrated Drug Substance and Drug Product Manufacturing
Others

Segment by Development and Commercialization Stage
Preclinical and IND-enabling Manufacturing
Phase I Clinical Manufacturing
Phase II Clinical Manufacturing
Phase III Clinical Manufacturing
Others

Segment by Application
Oncology
Immunology and Autoimmune Diseases
Infectious Diseases and Vaccines
Metabolic and Endocrine Diseases
Neurological Diseases
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Biologics CDMO study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Biologics CDMO: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biologics CDMO Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Biological Agent
1.2.3 Biosimilar Drug
1.3 Market Segmentation by Manufacturing Service Type
1.3.1 Global Biologics CDMO Market Size by Manufacturing Service Type, 2021 vs 2025 vs 2032
1.3.2 Drug Substance Manufacturing
1.3.3 Drug Product Manufacturing
1.3.4 Integrated Drug Substance and Drug Product Manufacturing
1.3.5 Others
1.4 Market Segmentation by Development and Commercialization Stage
1.4.1 Global Biologics CDMO Market Size by Development and Commercialization Stage, 2021 vs 2025 vs 2032
1.4.2 Preclinical and IND-enabling Manufacturing
1.4.3 Phase I Clinical Manufacturing
1.4.4 Phase II Clinical Manufacturing
1.4.5 Phase III Clinical Manufacturing
1.4.6 Others
1.5 Market Segmentation by Application
1.5.1 Global Biologics CDMO Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Oncology
1.5.3 Immunology and Autoimmune Diseases
1.5.4 Infectious Diseases and Vaccines
1.5.5 Metabolic and Endocrine Diseases
1.5.6 Neurological Diseases
1.5.7 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Biologics CDMO Revenue Estimates and Forecasts (2021-2032)
2.2 Global Biologics CDMO Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Biologics CDMO Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Biologics CDMO Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Biological Agent: Market Share by Key Players
3.3.2 Biosimilar Drug: Market Share by Key Players
3.4 Global Biologics CDMO Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Biologics CDMO Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Biologics CDMO Market by Manufacturing Service Type
4.2.1 Global Revenue by Manufacturing Service Type (2021-2032)
4.2.2 Global Revenue-Based Market Share by Manufacturing Service Type (2021-2032)
4.3 Global Biologics CDMO Market by Development and Commercialization Stage
4.3.1 Global Revenue by Development and Commercialization Stage (2021-2032)
4.3.2 Global Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Biologics CDMO Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Biologics CDMO Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Biologics CDMO Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Biologics CDMO Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Biologics CDMO Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Biologics CDMO Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Biologics CDMO Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Biologics CDMO Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Biologics CDMO Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Biologics CDMO Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Biologics CDMO Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Lonza Group AG
11.1.1 Lonza Group AG Corporation Information
11.1.2 Lonza Group AG Business Overview
11.1.3 Lonza Group AG Biologics CDMO Product Features and Attributes
11.1.4 Lonza Group AG Biologics CDMO Revenue and Gross Margin (2021-2026)
11.1.5 Lonza Group AG Biologics CDMO Revenue by Product in 2025
11.1.6 Lonza Group AG Biologics CDMO Revenue by Application in 2025
11.1.7 Lonza Group AG Biologics CDMO Revenue by Geographic Area in 2025
11.1.8 Lonza Group AG Biologics CDMO SWOT Analysis
11.1.9 Lonza Group AG Recent Developments
11.2 Samsung Biologics Co., Ltd.
11.2.1 Samsung Biologics Co., Ltd. Corporation Information
11.2.2 Samsung Biologics Co., Ltd. Business Overview
11.2.3 Samsung Biologics Co., Ltd. Biologics CDMO Product Features and Attributes
11.2.4 Samsung Biologics Co., Ltd. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.2.5 Samsung Biologics Co., Ltd. Biologics CDMO Revenue by Product in 2025
11.2.6 Samsung Biologics Co., Ltd. Biologics CDMO Revenue by Application in 2025
11.2.7 Samsung Biologics Co., Ltd. Biologics CDMO Revenue by Geographic Area in 2025
11.2.8 Samsung Biologics Co., Ltd. Biologics CDMO SWOT Analysis
11.2.9 Samsung Biologics Co., Ltd. Recent Developments
11.3 WuXi Biologics (Cayman) Inc.
11.3.1 WuXi Biologics (Cayman) Inc. Corporation Information
11.3.2 WuXi Biologics (Cayman) Inc. Business Overview
11.3.3 WuXi Biologics (Cayman) Inc. Biologics CDMO Product Features and Attributes
11.3.4 WuXi Biologics (Cayman) Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.3.5 WuXi Biologics (Cayman) Inc. Biologics CDMO Revenue by Product in 2025
11.3.6 WuXi Biologics (Cayman) Inc. Biologics CDMO Revenue by Application in 2025
11.3.7 WuXi Biologics (Cayman) Inc. Biologics CDMO Revenue by Geographic Area in 2025
11.3.8 WuXi Biologics (Cayman) Inc. Biologics CDMO SWOT Analysis
11.3.9 WuXi Biologics (Cayman) Inc. Recent Developments
11.4 FUJIFILM Holdings Corporation
11.4.1 FUJIFILM Holdings Corporation Corporation Information
11.4.2 FUJIFILM Holdings Corporation Business Overview
11.4.3 FUJIFILM Holdings Corporation Biologics CDMO Product Features and Attributes
11.4.4 FUJIFILM Holdings Corporation Biologics CDMO Revenue and Gross Margin (2021-2026)
11.4.5 FUJIFILM Holdings Corporation Biologics CDMO Revenue by Product in 2025
11.4.6 FUJIFILM Holdings Corporation Biologics CDMO Revenue by Application in 2025
11.4.7 FUJIFILM Holdings Corporation Biologics CDMO Revenue by Geographic Area in 2025
11.4.8 FUJIFILM Holdings Corporation Biologics CDMO SWOT Analysis
11.4.9 FUJIFILM Holdings Corporation Recent Developments
11.5 AGC Inc.
11.5.1 AGC Inc. Corporation Information
11.5.2 AGC Inc. Business Overview
11.5.3 AGC Inc. Biologics CDMO Product Features and Attributes
11.5.4 AGC Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.5.5 AGC Inc. Biologics CDMO Revenue by Product in 2025
11.5.6 AGC Inc. Biologics CDMO Revenue by Application in 2025
11.5.7 AGC Inc. Biologics CDMO Revenue by Geographic Area in 2025
11.5.8 AGC Inc. Biologics CDMO SWOT Analysis
11.5.9 AGC Inc. Recent Developments
11.6 Boehringer Ingelheim International GmbH
11.6.1 Boehringer Ingelheim International GmbH Corporation Information
11.6.2 Boehringer Ingelheim International GmbH Business Overview
11.6.3 Boehringer Ingelheim International GmbH Biologics CDMO Product Features and Attributes
11.6.4 Boehringer Ingelheim International GmbH Biologics CDMO Revenue and Gross Margin (2021-2026)
11.6.5 Boehringer Ingelheim International GmbH Recent Developments
11.7 Thermo Fisher Scientific Inc.
11.7.1 Thermo Fisher Scientific Inc. Corporation Information
11.7.2 Thermo Fisher Scientific Inc. Business Overview
11.7.3 Thermo Fisher Scientific Inc. Biologics CDMO Product Features and Attributes
11.7.4 Thermo Fisher Scientific Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.7.5 Thermo Fisher Scientific Inc. Recent Developments
11.8 Novo Holdings A/S
11.8.1 Novo Holdings A/S Corporation Information
11.8.2 Novo Holdings A/S Business Overview
11.8.3 Novo Holdings A/S Biologics CDMO Product Features and Attributes
11.8.4 Novo Holdings A/S Biologics CDMO Revenue and Gross Margin (2021-2026)
11.8.5 Novo Holdings A/S Recent Developments
11.9 Rentschler Biopharma SE
11.9.1 Rentschler Biopharma SE Corporation Information
11.9.2 Rentschler Biopharma SE Business Overview
11.9.3 Rentschler Biopharma SE Biologics CDMO Product Features and Attributes
11.9.4 Rentschler Biopharma SE Biologics CDMO Revenue and Gross Margin (2021-2026)
11.9.5 Rentschler Biopharma SE Recent Developments
11.10 KBI Biopharma, Inc.
11.10.1 KBI Biopharma, Inc. Corporation Information
11.10.2 KBI Biopharma, Inc. Business Overview
11.10.3 KBI Biopharma, Inc. Biologics CDMO Product Features and Attributes
11.10.4 KBI Biopharma, Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Ajinomoto Co., Inc.
11.11.1 Ajinomoto Co., Inc. Corporation Information
11.11.2 Ajinomoto Co., Inc. Business Overview
11.11.3 Ajinomoto Co., Inc. Biologics CDMO Product Features and Attributes
11.11.4 Ajinomoto Co., Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.11.5 Ajinomoto Co., Inc. Recent Developments
11.12 LOTTE BIOLOGICS
11.12.1 LOTTE BIOLOGICS Corporation Information
11.12.2 LOTTE BIOLOGICS Business Overview
11.12.3 LOTTE BIOLOGICS Biologics CDMO Product Features and Attributes
11.12.4 LOTTE BIOLOGICS Biologics CDMO Revenue and Gross Margin (2021-2026)
11.12.5 LOTTE BIOLOGICS Recent Developments
11.13 Polpharma Biologics
11.13.1 Polpharma Biologics Corporation Information
11.13.2 Polpharma Biologics Business Overview
11.13.3 Polpharma Biologics Biologics CDMO Product Features and Attributes
11.13.4 Polpharma Biologics Biologics CDMO Revenue and Gross Margin (2021-2026)
11.13.5 Polpharma Biologics Recent Developments
11.14 EirGenix, Inc.
11.14.1 EirGenix, Inc. Corporation Information
11.14.2 EirGenix, Inc. Business Overview
11.14.3 EirGenix, Inc. Biologics CDMO Product Features and Attributes
11.14.4 EirGenix, Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.14.5 EirGenix, Inc. Recent Developments
11.15 Richter-Helm BioLogics GmbH & Co. KG
11.15.1 Richter-Helm BioLogics GmbH & Co. KG Corporation Information
11.15.2 Richter-Helm BioLogics GmbH & Co. KG Business Overview
11.15.3 Richter-Helm BioLogics GmbH & Co. KG Biologics CDMO Product Features and Attributes
11.15.4 Richter-Helm BioLogics GmbH & Co. KG Biologics CDMO Revenue and Gross Margin (2021-2026)
11.15.5 Richter-Helm BioLogics GmbH & Co. KG Recent Developments
11.16 Simtra BioPharma Solutions
11.16.1 Simtra BioPharma Solutions Corporation Information
11.16.2 Simtra BioPharma Solutions Business Overview
11.16.3 Simtra BioPharma Solutions Biologics CDMO Product Features and Attributes
11.16.4 Simtra BioPharma Solutions Biologics CDMO Revenue and Gross Margin (2021-2026)
11.16.5 Simtra BioPharma Solutions Recent Developments
11.17 Vetter Pharma-Fertigung GmbH & Co. KG
11.17.1 Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
11.17.2 Vetter Pharma-Fertigung GmbH & Co. KG Business Overview
11.17.3 Vetter Pharma-Fertigung GmbH & Co. KG Biologics CDMO Product Features and Attributes
11.17.4 Vetter Pharma-Fertigung GmbH & Co. KG Biologics CDMO Revenue and Gross Margin (2021-2026)
11.17.5 Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
11.18 Piramal Pharma Limited
11.18.1 Piramal Pharma Limited Corporation Information
11.18.2 Piramal Pharma Limited Business Overview
11.18.3 Piramal Pharma Limited Biologics CDMO Product Features and Attributes
11.18.4 Piramal Pharma Limited Biologics CDMO Revenue and Gross Margin (2021-2026)
11.18.5 Piramal Pharma Limited Recent Developments
11.19 AbbVie Inc.
11.19.1 AbbVie Inc. Corporation Information
11.19.2 AbbVie Inc. Business Overview
11.19.3 AbbVie Inc. Biologics CDMO Product Features and Attributes
11.19.4 AbbVie Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.19.5 AbbVie Inc. Recent Developments
11.20 Emergent BioSolutions Inc.
11.20.1 Emergent BioSolutions Inc. Corporation Information
11.20.2 Emergent BioSolutions Inc. Business Overview
11.20.3 Emergent BioSolutions Inc. Biologics CDMO Product Features and Attributes
11.20.4 Emergent BioSolutions Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.20.5 Emergent BioSolutions Inc. Recent Developments
11.21 SK pharmteco
11.21.1 SK pharmteco Corporation Information
11.21.2 SK pharmteco Business Overview
11.21.3 SK pharmteco Biologics CDMO Product Features and Attributes
11.21.4 SK pharmteco Biologics CDMO Revenue and Gross Margin (2021-2026)
11.21.5 SK pharmteco Recent Developments
11.22 Oxford Biomedica plc
11.22.1 Oxford Biomedica plc Corporation Information
11.22.2 Oxford Biomedica plc Business Overview
11.22.3 Oxford Biomedica plc Biologics CDMO Product Features and Attributes
11.22.4 Oxford Biomedica plc Biologics CDMO Revenue and Gross Margin (2021-2026)
11.22.5 Oxford Biomedica plc Recent Developments
11.23 WuXi XDC Cayman Inc.
11.23.1 WuXi XDC Cayman Inc. Corporation Information
11.23.2 WuXi XDC Cayman Inc. Business Overview
11.23.3 WuXi XDC Cayman Inc. Biologics CDMO Product Features and Attributes
11.23.4 WuXi XDC Cayman Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.23.5 WuXi XDC Cayman Inc. Recent Developments
11.24 Porton Pharma Solutions Ltd.
11.24.1 Porton Pharma Solutions Ltd. Corporation Information
11.24.2 Porton Pharma Solutions Ltd. Business Overview
11.24.3 Porton Pharma Solutions Ltd. Biologics CDMO Product Features and Attributes
11.24.4 Porton Pharma Solutions Ltd. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.24.5 Porton Pharma Solutions Ltd. Recent Developments
11.25 Asymchem Laboratories (Tianjin) Co., Ltd.
11.25.1 Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
11.25.2 Asymchem Laboratories (Tianjin) Co., Ltd. Business Overview
11.25.3 Asymchem Laboratories (Tianjin) Co., Ltd. Biologics CDMO Product Features and Attributes
11.25.4 Asymchem Laboratories (Tianjin) Co., Ltd. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.25.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
11.26 BioVectra Inc.
11.26.1 BioVectra Inc. Corporation Information
11.26.2 BioVectra Inc. Business Overview
11.26.3 BioVectra Inc. Biologics CDMO Product Features and Attributes
11.26.4 BioVectra Inc. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.26.5 BioVectra Inc. Recent Developments
11.27 Bora Pharmaceuticals Co., Ltd.
11.27.1 Bora Pharmaceuticals Co., Ltd. Corporation Information
11.27.2 Bora Pharmaceuticals Co., Ltd. Business Overview
11.27.3 Bora Pharmaceuticals Co., Ltd. Biologics CDMO Product Features and Attributes
11.27.4 Bora Pharmaceuticals Co., Ltd. Biologics CDMO Revenue and Gross Margin (2021-2026)
11.27.5 Bora Pharmaceuticals Co., Ltd. Recent Developments
11.28 Recipharm AB
11.28.1 Recipharm AB Corporation Information
11.28.2 Recipharm AB Business Overview
11.28.3 Recipharm AB Biologics CDMO Product Features and Attributes
11.28.4 Recipharm AB Biologics CDMO Revenue and Gross Margin (2021-2026)
11.28.5 Recipharm AB Recent Developments
11.29 Minaris Regenerative Medicine
11.29.1 Minaris Regenerative Medicine Corporation Information
11.29.2 Minaris Regenerative Medicine Business Overview
11.29.3 Minaris Regenerative Medicine Biologics CDMO Product Features and Attributes
11.29.4 Minaris Regenerative Medicine Biologics CDMO Revenue and Gross Margin (2021-2026)
11.29.5 Minaris Regenerative Medicine Recent Developments
11.30 Cellipont Bioservices
11.30.1 Cellipont Bioservices Corporation Information
11.30.2 Cellipont Bioservices Business Overview
11.30.3 Cellipont Bioservices Biologics CDMO Product Features and Attributes
11.30.4 Cellipont Bioservices Biologics CDMO Revenue and Gross Margin (2021-2026)
11.30.5 Cellipont Bioservices Recent Developments
11.31 Andelyn Biosciences
11.31.1 Andelyn Biosciences Corporation Information
11.31.2 Andelyn Biosciences Business Overview
11.31.3 Andelyn Biosciences Biologics CDMO Product Features and Attributes
11.31.4 Andelyn Biosciences Biologics CDMO Revenue and Gross Margin (2021-2026)
11.31.5 Andelyn Biosciences Recent Developments
11.32 Danaher Corporation
11.32.1 Danaher Corporation Corporation Information
11.32.2 Danaher Corporation Business Overview
11.32.3 Danaher Corporation Biologics CDMO Product Features and Attributes
11.32.4 Danaher Corporation Biologics CDMO Revenue and Gross Margin (2021-2026)
11.32.5 Danaher Corporation Recent Developments
11.33 BioCina
11.33.1 BioCina Corporation Information
11.33.2 BioCina Business Overview
11.33.3 BioCina Biologics CDMO Product Features and Attributes
11.33.4 BioCina Biologics CDMO Revenue and Gross Margin (2021-2026)
11.33.5 BioCina Recent Developments
11.34 Syngene International Limited
11.34.1 Syngene International Limited Corporation Information
11.34.2 Syngene International Limited Business Overview
11.34.3 Syngene International Limited Biologics CDMO Product Features and Attributes
11.34.4 Syngene International Limited Biologics CDMO Revenue and Gross Margin (2021-2026)
11.34.5 Syngene International Limited Recent Developments
11.35 Aragen Life Sciences
11.35.1 Aragen Life Sciences Corporation Information
11.35.2 Aragen Life Sciences Business Overview
11.35.3 Aragen Life Sciences Biologics CDMO Product Features and Attributes
11.35.4 Aragen Life Sciences Biologics CDMO Revenue and Gross Margin (2021-2026)
11.35.5 Aragen Life Sciences Recent Developments
11.36 MabPlex International
11.36.1 MabPlex International Corporation Information
11.36.2 MabPlex International Business Overview
11.36.3 MabPlex International Biologics CDMO Product Features and Attributes
11.36.4 MabPlex International Biologics CDMO Revenue and Gross Margin (2021-2026)
11.36.5 MabPlex International Recent Developments
11.37 GenScript Biotech Corporation
11.37.1 GenScript Biotech Corporation Corporation Information
11.37.2 GenScript Biotech Corporation Business Overview
11.37.3 GenScript Biotech Corporation Biologics CDMO Product Features and Attributes
11.37.4 GenScript Biotech Corporation Biologics CDMO Revenue and Gross Margin (2021-2026)
11.37.5 GenScript Biotech Corporation Recent Developments
11.38 Chime Biologics
11.38.1 Chime Biologics Corporation Information
11.38.2 Chime Biologics Business Overview
11.38.3 Chime Biologics Biologics CDMO Product Features and Attributes
11.38.4 Chime Biologics Biologics CDMO Revenue and Gross Margin (2021-2026)
11.38.5 Chime Biologics Recent Developments
11.39 Hangzhou HJB
11.39.1 Hangzhou HJB Corporation Information
11.39.2 Hangzhou HJB Business Overview
11.39.3 Hangzhou HJB Biologics CDMO Product Features and Attributes
11.39.4 Hangzhou HJB Biologics CDMO Revenue and Gross Margin (2021-2026)
11.39.5 Hangzhou HJB Recent Developments
11.40 BiBo Pharma
11.40.1 BiBo Pharma Corporation Information
11.40.2 BiBo Pharma Business Overview
11.40.3 BiBo Pharma Biologics CDMO Product Features and Attributes
11.40.4 BiBo Pharma Biologics CDMO Revenue and Gross Margin (2021-2026)
11.40.5 BiBo Pharma Recent Developments

12 Biologics CDMO Value Chain and Ecosystem Analysis
12.1 Biologics CDMO Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Biologics CDMO Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Biologics CDMO Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Biologics CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Biologics CDMO Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Biologics CDMO Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Biologics CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Biologics CDMO Revenue by Region (US$ Million), 2021-2026
Table 7. Global Biologics CDMO Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Biologics CDMO Revenue by Players (US$ Million), 2021-2026
Table 10. Global Biologics CDMO Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics CDMO Revenue, 2025
Table 13. Global Biologics CDMO Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Biologics CDMO Companies Headquarters
Table 15. Global Biologics CDMO Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Biologics CDMO Revenue by Type (US$ Million), 2021-2026
Table 19. Global Biologics CDMO Revenue by Type (US$ Million), 2027-2032
Table 20. Global Biologics CDMO Revenue by Manufacturing Service Type (US$ Million), 2021-2026
Table 21. Global Biologics CDMO Revenue by Manufacturing Service Type (US$ Million), 2027-2032
Table 22. Global Biologics CDMO Revenue by Development and Commercialization Stage (US$ Million), 2021-2026
Table 23. Global Biologics CDMO Revenue by Development and Commercialization Stage (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Biologics CDMO Revenue by Application (US$ Million), 2021-2026
Table 26. Global Biologics CDMO Revenue by Application (US$ Million), 2027-2032
Table 27. Biologics CDMO High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Biologics CDMO Growth Accelerators and Market Barriers
Table 31. North America Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Biologics CDMO Growth Accelerators and Market Barriers
Table 33. Europe Biologics CDMO Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Biologics CDMO Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Biologics CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Biologics CDMO Investment Opportunities and Key Challenges
Table 37. Central and South America Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Biologics CDMO Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Biologics CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Group AG Corporation Information
Table 41. Lonza Group AG Description and Major Businesses
Table 42. Lonza Group AG Product Features and Attributes
Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Group AG Revenue Proportion by Product in 2025
Table 45. Lonza Group AG Revenue Proportion by Application in 2025
Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Group AG Biologics CDMO SWOT Analysis
Table 48. Lonza Group AG Recent Developments
Table 49. Samsung Biologics Co., Ltd. Corporation Information
Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses
Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes
Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025
Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025
Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025
Table 56. Samsung Biologics Co., Ltd. Biologics CDMO SWOT Analysis
Table 57. Samsung Biologics Co., Ltd. Recent Developments
Table 58. WuXi Biologics (Cayman) Inc. Corporation Information
Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses
Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes
Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025
Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025
Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025
Table 65. WuXi Biologics (Cayman) Inc. Biologics CDMO SWOT Analysis
Table 66. WuXi Biologics (Cayman) Inc. Recent Developments
Table 67. FUJIFILM Holdings Corporation Corporation Information
Table 68. FUJIFILM Holdings Corporation Description and Major Businesses
Table 69. FUJIFILM Holdings Corporation Product Features and Attributes
Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025
Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025
Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025
Table 74. FUJIFILM Holdings Corporation Biologics CDMO SWOT Analysis
Table 75. FUJIFILM Holdings Corporation Recent Developments
Table 76. AGC Inc. Corporation Information
Table 77. AGC Inc. Description and Major Businesses
Table 78. AGC Inc. Product Features and Attributes
Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. AGC Inc. Revenue Proportion by Product in 2025
Table 81. AGC Inc. Revenue Proportion by Application in 2025
Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025
Table 83. AGC Inc. Biologics CDMO SWOT Analysis
Table 84. AGC Inc. Recent Developments
Table 85. Boehringer Ingelheim International GmbH Corporation Information
Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses
Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes
Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Boehringer Ingelheim International GmbH Recent Developments
Table 90. Thermo Fisher Scientific Inc. Corporation Information
Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Thermo Fisher Scientific Inc. Recent Developments
Table 95. Novo Holdings A/S Corporation Information
Table 96. Novo Holdings A/S Description and Major Businesses
Table 97. Novo Holdings A/S Product Features and Attributes
Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Novo Holdings A/S Recent Developments
Table 100. Rentschler Biopharma SE Corporation Information
Table 101. Rentschler Biopharma SE Description and Major Businesses
Table 102. Rentschler Biopharma SE Product Features and Attributes
Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Rentschler Biopharma SE Recent Developments
Table 105. KBI Biopharma, Inc. Corporation Information
Table 106. KBI Biopharma, Inc. Description and Major Businesses
Table 107. KBI Biopharma, Inc. Product Features and Attributes
Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. KBI Biopharma, Inc. Recent Developments
Table 110. Ajinomoto Co., Inc. Corporation Information
Table 111. Ajinomoto Co., Inc. Description and Major Businesses
Table 112. Ajinomoto Co., Inc. Product Features and Attributes
Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Ajinomoto Co., Inc. Recent Developments
Table 115. LOTTE BIOLOGICS Corporation Information
Table 116. LOTTE BIOLOGICS Description and Major Businesses
Table 117. LOTTE BIOLOGICS Product Features and Attributes
Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. LOTTE BIOLOGICS Recent Developments
Table 120. Polpharma Biologics Corporation Information
Table 121. Polpharma Biologics Description and Major Businesses
Table 122. Polpharma Biologics Product Features and Attributes
Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Polpharma Biologics Recent Developments
Table 125. EirGenix, Inc. Corporation Information
Table 126. EirGenix, Inc. Description and Major Businesses
Table 127. EirGenix, Inc. Product Features and Attributes
Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. EirGenix, Inc. Recent Developments
Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information
Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses
Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes
Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments
Table 135. Simtra BioPharma Solutions Corporation Information
Table 136. Simtra BioPharma Solutions Description and Major Businesses
Table 137. Simtra BioPharma Solutions Product Features and Attributes
Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Simtra BioPharma Solutions Recent Developments
Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses
Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes
Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
Table 145. Piramal Pharma Limited Corporation Information
Table 146. Piramal Pharma Limited Description and Major Businesses
Table 147. Piramal Pharma Limited Product Features and Attributes
Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Piramal Pharma Limited Recent Developments
Table 150. AbbVie Inc. Corporation Information
Table 151. AbbVie Inc. Description and Major Businesses
Table 152. AbbVie Inc. Product Features and Attributes
Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. AbbVie Inc. Recent Developments
Table 155. Emergent BioSolutions Inc. Corporation Information
Table 156. Emergent BioSolutions Inc. Description and Major Businesses
Table 157. Emergent BioSolutions Inc. Product Features and Attributes
Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Emergent BioSolutions Inc. Recent Developments
Table 160. SK pharmteco Corporation Information
Table 161. SK pharmteco Description and Major Businesses
Table 162. SK pharmteco Product Features and Attributes
Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. SK pharmteco Recent Developments
Table 165. Oxford Biomedica plc Corporation Information
Table 166. Oxford Biomedica plc Description and Major Businesses
Table 167. Oxford Biomedica plc Product Features and Attributes
Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Oxford Biomedica plc Recent Developments
Table 170. WuXi XDC Cayman Inc. Corporation Information
Table 171. WuXi XDC Cayman Inc. Description and Major Businesses
Table 172. WuXi XDC Cayman Inc. Product Features and Attributes
Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. WuXi XDC Cayman Inc. Recent Developments
Table 175. Porton Pharma Solutions Ltd. Corporation Information
Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses
Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes
Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Porton Pharma Solutions Ltd. Recent Developments
Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses
Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes
Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
Table 185. BioVectra Inc. Corporation Information
Table 186. BioVectra Inc. Description and Major Businesses
Table 187. BioVectra Inc. Product Features and Attributes
Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. BioVectra Inc. Recent Developments
Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information
Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses
Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes
Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments
Table 195. Recipharm AB Corporation Information
Table 196. Recipharm AB Description and Major Businesses
Table 197. Recipharm AB Product Features and Attributes
Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Recipharm AB Recent Developments
Table 200. Minaris Regenerative Medicine Corporation Information
Table 201. Minaris Regenerative Medicine Description and Major Businesses
Table 202. Minaris Regenerative Medicine Product Features and Attributes
Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Minaris Regenerative Medicine Recent Developments
Table 205. Cellipont Bioservices Corporation Information
Table 206. Cellipont Bioservices Description and Major Businesses
Table 207. Cellipont Bioservices Product Features and Attributes
Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Cellipont Bioservices Recent Developments
Table 210. Andelyn Biosciences Corporation Information
Table 211. Andelyn Biosciences Description and Major Businesses
Table 212. Andelyn Biosciences Product Features and Attributes
Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Andelyn Biosciences Recent Developments
Table 215. Danaher Corporation Corporation Information
Table 216. Danaher Corporation Description and Major Businesses
Table 217. Danaher Corporation Product Features and Attributes
Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Danaher Corporation Recent Developments
Table 220. BioCina Corporation Information
Table 221. BioCina Description and Major Businesses
Table 222. BioCina Product Features and Attributes
Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. BioCina Recent Developments
Table 225. Syngene International Limited Corporation Information
Table 226. Syngene International Limited Description and Major Businesses
Table 227. Syngene International Limited Product Features and Attributes
Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Syngene International Limited Recent Developments
Table 230. Aragen Life Sciences Corporation Information
Table 231. Aragen Life Sciences Description and Major Businesses
Table 232. Aragen Life Sciences Product Features and Attributes
Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. Aragen Life Sciences Recent Developments
Table 235. MabPlex International Corporation Information
Table 236. MabPlex International Description and Major Businesses
Table 237. MabPlex International Product Features and Attributes
Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. MabPlex International Recent Developments
Table 240. GenScript Biotech Corporation Corporation Information
Table 241. GenScript Biotech Corporation Description and Major Businesses
Table 242. GenScript Biotech Corporation Product Features and Attributes
Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. GenScript Biotech Corporation Recent Developments
Table 245. Chime Biologics Corporation Information
Table 246. Chime Biologics Description and Major Businesses
Table 247. Chime Biologics Product Features and Attributes
Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Chime Biologics Recent Developments
Table 250. Hangzhou HJB Corporation Information
Table 251. Hangzhou HJB Description and Major Businesses
Table 252. Hangzhou HJB Product Features and Attributes
Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Hangzhou HJB Recent Developments
Table 255. BiBo Pharma Corporation Information
Table 256. BiBo Pharma Description and Major Businesses
Table 257. BiBo Pharma Product Features and Attributes
Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 259. BiBo Pharma Recent Developments
Table 260. Technologies, Platforms and Infrastructure
Table 261. Distributors List
Table 262. Market Trends and Market Evolution
Table 263. Market Drivers and Opportunities
Table 264. Market Challenges, Risks, and Restraints
Table 265. Research Programs/Design for This Report
Table 266. Key Data Information from Secondary Sources
Table 267. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Biologics CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Biological Agent Product Picture
Figure 3. Biosimilar Drug Product Picture
Figure 4. Global Biologics CDMO Market Size Growth Rate by Manufacturing Service Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 5. Drug Substance Manufacturing Product Picture
Figure 6. Drug Product Manufacturing Product Picture
Figure 7. Integrated Drug Substance and Drug Product Manufacturing Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biologics CDMO Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Preclinical and IND-enabling Manufacturing Product Picture
Figure 11. Phase I Clinical Manufacturing Product Picture
Figure 12. Phase II Clinical Manufacturing Product Picture
Figure 13. Phase III Clinical Manufacturing Product Picture
Figure 14. Others Product Picture
Figure 15. Global Biologics CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Oncology
Figure 17. Immunology and Autoimmune Diseases
Figure 18. Infectious Diseases and Vaccines
Figure 19. Metabolic and Endocrine Diseases
Figure 20. Neurological Diseases
Figure 21. Others
Figure 22. Biologics CDMO Report Years Considered
Figure 23. Global Biologics CDMO Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 24. Global Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 25. Global Biologics CDMO Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 26. Global Biologics CDMO Revenue-Based Market Share by Region (2021-2032)
Figure 27. Global Biologics CDMO Revenue-Based Market Share Ranking (2025)
Figure 28. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 29. Biological Agent Revenue-Based Market Share by Player in 2025
Figure 30. Biosimilar Drug Revenue-Based Market Share by Player in 2025
Figure 31. Global Biologics CDMO Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Biologics CDMO Revenue-Based Market Share by Manufacturing Service Type (2021-2032)
Figure 33. Global Biologics CDMO Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
Figure 34. Global Biologics CDMO Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 37. North America Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 39. Canada Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 40. Mexico Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 41. Europe Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 43. Europe Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 45. France Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 46. U.K. Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 47. Italy Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 48. Russia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 53. Japan Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 54. South Korea Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 55. Australia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 56. India Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 60. Philippines Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 61. Singapore Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 64. Central and South America Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 66. Argentina Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Biologics CDMO Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Biologics CDMO Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Biologics CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 71. Israel Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 72. Egypt Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 73. South Africa Biologics CDMO Revenue (US$ Million), 2021-2032
Figure 74. Biologics CDMO Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(biologics)の最新刊レポート



関連レポート(キーワード「バイオ医薬品」)


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/20 10:25

160.51 円

176.53 円

212.83 円

ページTOPに戻る